Abstract: The invention relates to compositions and methods for isolating extracellular vesicles (EVs) from a biological fluid sample. The compositions and methods of the invention are based on the combination of a polycation with an extracellular matrix forming polymer. Extracellular vesicles (EVs) are isolated from biological fluids such as blood, serum, plasma, saliva, urine or cerebrospinal fluid, or from the conditioned medium of a cell culture, such as an adult stem cell culture. The use of the isolation methods and compositions of the invention results in a higher EVs recovery, enrichment in exosomes, simplicity, cost-effectiveness, and in the isolation of EVs that retain their biological activities in vitro.

Abstract: The invention relates to a method and a kit for capturing on a solid surface the extracellular vesicles (EVs) which are present in a biological fluid sample. The solid surface is coated with a polycationic substance, preferably a protamine salt such as protamine hydrochloride. The method and kit of the invention is useful for the detection and/or quantification of the extracellular vesicles (EVs) which are present in a biological fluid sample, particularly in a diagnostic context.

Abstract: The invention relates to compositions and methods for isolating extracellular vesicles (EVs) from a biological fluid sample. The compositions and methods of the invention are based on the combination of a polycation with an extracellular matrix forming polymer. Extracellular vesicles (EVs) are isolated from biological fluids such as blood, serum, plasma, saliva, urine or cerebrospinal fluid, or from the conditioned medium of a cell culture, such as an adult stem cell culture. The use of the isolation methods and compositions of the invention results in a higher EVs recovery, enrichment in exosomes, simplicity, cost-effectiveness, and in the isolation of EVs that retain their biological activities in vitro.

Abstract: The invention relates to the use of microvesicles (MVs) derived from stem cells for preparing a medicament for the endo/epithelial regeneration of damaged tissues or organs and/or for inhibiting the apoptosis induced by cytostatic agents. The stem cell from which the microvesicles are obtained is preferably selected from the group consisting of endothelial progenitor cells (EPCs), mesenchimal stem cells (MSCs), renal progenitors CD1 33+, adult human liver stem cells (HLSC) and any combination thereof. The microvesicles may be used in both in vitro and in vivo applications, such as for example the regeneration of damaged tissues or organs and the treatment of renal injury and hepatic injury, particularly acute renal failure (ARF) and acute hepatic failure (AHF).

Abstract: The invention relates to the use of microvesicles (MVs) derived from stem cells for preparing a medicament for the endo/epithelial regeneration of damaged tissues or organs and/or for inhibiting the apoptosis induced by cytostatic agents. The stem cell from which the microvesicles are obtained is preferably selected from the group consisting of endothelial progenitor cells (EPCs), mesenchimal stem cells (MSCs), renal progenitors CD1 33+, adult human liver stem cells (HLSC) and any combination thereof. The microvesicles may be used in both in vitro and in vivo applications, such as for example the regeneration of damaged tissues or organs and the treatment of renal injury and hepatic injury, particularly acute renal failure (ARF) and acute hepatic failure (AHF).